Jeff Galvin Is Taking a New Approach to Medicine There’s a revolution brewing in medicine, and the paradigm-shifting innovations in the gene and cell therapy space are right at the heart of the movement. Jeff Galvin, CEO of American Gene Technologies® (AGT ™) and Addimmune™, has seen firsthand what gene and cell therapies can do. With a background… How does Jeff Galvin, CEO of Addimmune, THINK? appeared first on American Gene Technologies ..read more

The silent HIV epidemic has been ongoing for 4 decades. AIDS-related illnesses have claimed over 32 million lives since the beginning of the HIV epidemic in 1981. The death toll, societal impact, and economic effects of the HIV epidemic have made HIV/AIDS one of the greatest public health threats the world has ever known. Governments,… Why Is It So Difficult to Find an HIV Cure? appeared first on American Gene Technologies ..read more

Contributing Author Luke Williams, Sales and Marketing  Under normal circumstances, exposure to HIV leads to infection, which inevitably leads to AIDS after years of virus-mediated destruction of the immune system.... [Read More] Challenge the narrative: HIV is a curable condition appeared first on American Gene Technologies ..read more

Contributing Author Luke Williams, Sales and Marketing  The cure for cancer is the holy grail of the medical sciences, so it may surprise you to learn that there are already... [Read More] How to Design a Gene Therapy to Target Cancer appeared first on American Gene Technologies ..read more

Rare disease, as the name suggests, affects a small proportion of the population and appears with low prevalence. The limited number of patients impedes development of new therapies, reducing the... [Read More] A Noble Pursuit: Gene Therapy for Rare Disease appeared first on American Gene Technologies ..read more

This is a lesson you won’t learn in school. We’re at an exciting stage in biotechnology today, on the cusp of revolutionizing how we treat some of humankind’s most deadly... [Read More] How to Design a Gene Therapy to Target Viruses appeared first on American Gene Technologies ..read more

[1] After a final burst of initial public offerings (IPOs) in early 2021, times have been difficult for life sciences public equities. S&P’s small cap biotech exchange traded fund, the... [Read More] Transaction Trends 2022: A Good Time to be a Private Company appeared first on American Gene Technologies ..read more

American Gene Technologies® CEO and founder Jeff Galvin was awarded the Life Sciences Voice 2023 Top Industry Leaders Award. The annual award recognizes the most dynamic leaders in the life... [Read More] Jeff Galvin Wins Life Sciences Voice Top Industry Leaders Award appeared first on American Gene Technologies ..read more

A mounting body of evidence shows that HIV, once thought to be an incurable lifelong condition, is indeed curable. The “Dusseldorf Patient” made headlines recently when a stem cell transplant... [Read More] HIV Has Been Cured For a 5th Time, Now Researchers Are Developing Scalable Methods appeared first on American Gene Technologies ..read more

Our world has been revolutionized by biotechnologies like CRISPR-based gene editing and mRNA vaccines. This vigorous advancement has been powered by female scientists, and the results have reshaped industries from... [Read More] The Future is Written by Female Scientists – In Genetic Code appeared first on American Gene Technologies ..read more